Full Press Release Details
Creative Medical Technology Holdings
Demonstrates AmnioStem Derived Exosomes Inhibit Glioma Growth
Company's Unique Stem Cell Nanotechnology
Approach Appears to Stimulate Regeneration of Healthy Brain Cells While Selectively Inhibiting Glioma Brain Cancer
SAN DIEGO and PHOENIX, July 25, 2017 /PRNewswire/ -- Creative
Medical Technology Holdings, Inc. (OTCQB:CELZ), a clinical stage stem cell company, announced preclinical data showing exosomes
harvested from its patented AmnioStem amniotic fluid stem cell, selectively inhibit growth of glioma brain cancer cells.
Exosomes are nanoparticles generated by a variety of cells that
are critically involved in intercellular communication. The Company previously filed patents on the use of AmnioStem derived exosomes
for treatment of stroke1. The AmnioStem
technology was originally licensed from the University of California San Diego (UCSD), under an exclusive agreement covering issued
US Patent #7,569,3852.
"Having seen first-hand the devastation and lack of treatment
options in glioma patients, I am excited about the prospect of developing a non-toxic biological approach that eventually may provide
benefit to this group of patients," said Santosh Kesari, MD, Ph.D, FANA, FAAN, Chair and Professor, Department of Translational
Neurosciences and Neurotherapeutics, John Wayne Cancer Institute, as well as Director of Neuro-oncology, Providence Saint John's
Health Center and leads the Pacific Neuroscience Research Center at Pacific Neuroscience Institute.
"The filed patent application contains data showing that
while AmnioStem derived exosomes inhibited proliferation of glioma cells, other stem cell types actually increased proliferation
of glioma," said Thomas Ichim, Ph.D, Chief Scientific Officer of Creative Medical Technology Holdings. "We are currently
working under the possibility that AmnioStem stem cells may possess unique biological properties that are different from other
types of stem cells."
"From a commercialization perspective, exosomes are simpler
to manufacture, store, and deliver as compared to living cells. Additionally, since exosomes are not replicating cells, we anticipate
a less complicated FDA regulatory pathway as compared to cellular based products," said Timothy Warbington, President and
CEO of Creative Medical Technology Holdings.
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a clinical stage
biotechnology company currently trading on the OTCQB under the ticker symbol CELZ. For further information about the company go
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited
to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc.
Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual
results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by
Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website
Chief Executive Officer